National Catholic Register9d
‘This Baby Is a Gift’: Trisomy 18 Awareness Day Reminds Us That Every Life Is Sacred
Tragically, many of the children who would be born are not given the opportunity to fight for their lives because the ...
Scientific Research Publishing8d
Evans, D. R. (2009). Neurofibromatosis Type 2 (NF2): A Clinical and Molecular Review. Orphanet Journal of Rare Diseases, 4, Article No. 16.
ABSTRACT: Schwannomas are benign, encapsulated tumors originating from Schwann cells, commonly found in the head and neck region. Although rare, lip schwannomas can occur and are typically ...
PharmiWeb8d
New data on investigational therapy for thymidine…
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
PharmiWeb10d
Eneboparatide met primary endpoint of normalising…
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
Le Lézard10d
SKYCLARYStm (omaveloxolone) Approval by Health Canada Ushers in a New Era for Friedreich's Ataxia Treatment in Canada
Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYStm (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This ...
Business Wire21d
Italfarmaco Provides Overview on Givinostat as Treatment for Duchenne Muscular Dystrophy: Progress in Global Access, Regulatory Milestones and Clinical Trials
MILAN--(BUSINESS WIRE)--Italfarmaco S.p.A. today announced a comprehensive update on the regulatory and clinical advancements for givinostat, the company’s drug for the treatment of Duchenne ...
PipelineReview.com10d
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
Scientific Research Publishing26d
Silent Growth: 18-Year History of an Upper Lip Schwannoma ()
Ouardi, K. , Hamama, J. , Harbili, M. , Ouraini, S. , Benariba, F. and Errami, N. (2025) Silent Growth: 18-Year History of an Upper Lip Schwannoma. Voice of the Publisher, 11, 128-135. doi: 10.4236/vp ...